ABS Investment Management’s Mirum Pharmaceuticals MIRM Stock Holding History

ABS Investment Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246K	Buy	+117	New	+$11.7K	0.15%	92

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ABS Investment Management's MIRM Position: Q2 2026 in Review

ABS Investment Management opened a new position in Mirum Pharmaceuticals (MIRM) in Q2 2026: 117 shares worth $246K. The stake represents 0.15% of the portfolio and ranks #92 among its holdings.

300 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

ABS Investment Management held 117 shares of Mirum Pharmaceuticals worth $246K as of Q2 2026.
Mirum Pharmaceuticals was a new ABS Investment Management position in Q2 2026.
Mirum Pharmaceuticals made up 0.15% of ABS Investment Management's portfolio in Q2 2026, its #92 holding.
300 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on ABS Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.